XML 48 R29.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Quarterly Operating Results (unaudited) | 12 Months Ended
--- | ---
Dec. 31, 2015
Quarterly Financial Data [Abstract] |
Quarterly Operating Results (unaudited) |
2015 (a) | First Quarter |  | Second Quarter |  | Third Quarter |  | Fourth Quarter |  | Total Year
| (b) |  | (c) |  | (d) |  | (e) |  |
Net revenues | $ | 1,839 |  |  | $ | 1,925 |  |  | $ | 1,880 |  |  | $ | 1,849 |  |  | $ | 7,493 |
Gross profit | 676 |  |  | 743 |  |  | 718 |  |  | 699 |  |  | 2,836 |
Income from continuing operations | 70 |  |  | 129 |  |  | 354 |  |  | 200 |  |  | 753 |
Income from discontinued operations, net of taxes | — |  |  | — |  |  | — |  |  | — |  |  | — |
Net income | 70 |  |  | 129 |  |  | 354 |  |  | 200 |  |  | 753 |
Less: Net income attributable to noncontrolling interests | 9 |  |  | 11 |  |  | 12 |  |  | 12 |  |  | 44 |
Net income attributable to Quest Diagnostics | $ | 61 |  |  | $ | 118 |  |  | $ | 342 |  |  | $ | 188 |  |  | $ | 709 |
Amounts attributable to Quest Diagnostics' stockholders: |  |  |  |  |  |  |  |  |
Income from continuing operations | $ | 61 |  |  | $ | 118 |  |  | $ | 342 |  |  | $ | 188 |  |  | $ | 709 |
Income from discontinued operations, net of taxes | — |  |  | — |  |  | — |  |  | — |  |  | — |
Net income | $ | 61 |  |  | $ | 118 |  |  | $ | 342 |  |  | $ | 188 |  |  | $ | 709 |
Earnings per share attributable to Quest Diagnostics' stockholders - basic: |  |  |  |  |  |  |  |  |
Income from continuing operations | $ | 0.42 |  |  | $ | 0.82 |  |  | $ | 2.37 |  |  | $ | 1.31 |  |  | $ | 4.92 |
Income from discontinued operations | — |  |  | — |  |  | — |  |  | — |  |  | — |
Net income | $ | 0.42 |  |  | $ | 0.82 |  |  | $ | 2.37 |  |  | $ | 1.31 |  |  | $ | 4.92 |
Earnings per share attributable to Quest Diagnostics' stockholders - diluted: |  |  |  |  |  |  |  |  |
Income from continuing operations | $ | 0.42 |  |  | $ | 0.81 |  |  | $ | 2.35 |  |  | $ | 1.29 |  |  | $ | 4.87 |
Income from discontinued operations | — |  |  | — |  |  | — |  |  | — |  |  | — |
Net income | $ | 0.42 |  |  | $ | 0.81 |  |  | $ | 2.35 |  |  | $ | 1.29 |  |  | $ | 4.87 |
2014 (a) | First Quarter |  | Second Quarter |  | Third Quarter |  | Fourth Quarter |  | Total Year
| (f) |  | (g) |  | (h) |  | (i) |  |
Net revenues | $ | 1,746 |  |  | $ | 1,902 |  |  | $ | 1,904 |  |  | $ | 1,883 |  |  | $ | 7,435 |
Gross profit | 645 |  |  | 728 |  |  | 726 |  |  | 699 |  |  | 2,798 |
Income from continuing operations | 111 |  |  | 142 |  |  | 139 |  |  | 195 |  |  | 587 |
Income from discontinued operations, net of taxes | — |  |  | — |  |  | — |  |  | 5 |  |  | 5 |
Net income | 111 |  |  | 142 |  |  | 139 |  |  | 200 |  |  | 592 |
Less: Net income attributable to noncontrolling interests | 7 |  |  | 9 |  |  | 10 |  |  | 10 |  |  | 36 |
Net income attributable to Quest Diagnostics | $ | 104 |  |  | $ | 133 |  |  | $ | 129 |  |  | $ | 190 |  |  | $ | 556 |
Amounts attributable to Quest Diagnostics' stockholders: |  |  |  |  |  |  |  |  |
Income from continuing operations | $ | 104 |  |  | $ | 133 |  |  | $ | 129 |  |  | $ | 185 |  |  | $ | 551 |
Income from discontinued operations, net of taxes | — |  |  | — |  |  | — |  |  | 5 |  |  | 5 |
Net income | $ | 104 |  |  | $ | 133 |  |  | $ | 129 |  |  | $ | 190 |  |  | $ | 556 |
Earnings per share attributable to Quest Diagnostics' stockholders - basic: |  |  |  |  |  |  |  |  |
Income from continuing operations | $ | 0.72 |  |  | $ | 0.92 |  |  | $ | 0.89 |  |  | $ | 1.27 |  |  | $ | 3.80 |
Income from discontinued operations | — |  |  | — |  |  | — |  |  | 0.03 |  |  | 0.03 |
Net income | $ | 0.72 |  |  | $ | 0.92 |  |  | $ | 0.89 |  |  | $ | 1.30 |  |  | $ | 3.83 |
Earnings per share attributable to Quest Diagnostics' stockholders - diluted: |  |  |  |  |  |  |  |  |
Income from continuing operations | $ | 0.71 |  |  | $ | 0.92 |  |  | $ | 0.88 |  |  | $ | 1.26 |  |  | $ | 3.78 |
Income from discontinued operations | — |  |  | — |  |  | — |  |  | 0.03 |  |  | 0.03 |
Net income | $ | 0.71 |  |  | $ | 0.92 |  |  | $ | 0.88 |  |  | $ | 1.29 |  |  | $ | 3.81 |
(a) | In April 2013, the Company completed the sale of HemoCue. During the third quarter of 2006, the Company completed its wind down of NID and classified the operations of NID as discontinued operations. Results of operations have been prepared to report the results of HemoCue and NID as discontinued operations for all periods presented (see Note 18). In July 2015, the Company contributed its clinical trials testing business to a newly formed global clinical trials central laboratory services joint venture, Q 2 Solutions. Subsequent to closing, the Company's ownership interest in the joint venture is being accounted for under the equity method of accounting.
(b) | Includes pre-tax charges of $31 million, primarily associated with workforce reductions and professional fees incurred in connection with further restructuring and integrating the Company ($20 million in cost of services and $11 million in selling, general and administrative expenses); pre-tax charges of $8 million in other operating expense (income), net, representing non-cash asset impairment charges associated with our Celera Products business; pre-tax charges in selling, general and administrative expenses of $2 million, principally representing costs incurred related to legal matters; and pre-tax charges of $79 million on retirement of debt associated with the March 2015 cash tender offer in other (expense) income, net (see Note 13).
(c) | Includes pre-tax charges of $23 million, primarily associated with workforce reductions and professional fees incurred in connection with further restructuring and integrating the Company ($11 million in cost of services and $12 million in selling, general and administrative expenses); a pre-tax gain included in other operating expense (income), net of $13 million associated with a decrease in the fair value of the contingent consideration accrual associated with our Summit Health acquisition (see Note 5 and Note 7); pre-tax charges in selling, general and administrative expenses of $5 million, principally representing costs incurred related to legal matters; pre-tax charges of $5 million in other operating expense (income), net, representing non-cash asset impairment charges; and pre-tax charges of $65 million on retirement of debt associated with the April 2015 redemption in other (expense) income, net (see Note 13).
(d) | Includes a pre-tax gain of $334 million associated with the contribution of the Company's clinical trials testing business to Q 2 Solutions (see Note 6); and pre-tax charges of $29 million, primarily associated with workforce reductions and professional fees incurred in connection with further restructuring and integrating the Company ($20 million in cost of services and $9 million in selling, general and administrative expenses).
(e) | Includes pre-tax charges of $22 million, primarily associated with workforce reductions and professional fees incurred in connection with further restructuring and integrating the Company ($12 million in cost of services and $10 million in selling, general and administrative expenses); pre-tax charges of $11 million in other operating expense (income), net, representing non-cash asset impairment charges associated with winding down a subsidiary; and pre-tax charges in selling, general and administrative expenses of $10 million, principally representing costs incurred related to legal matters. Income from continuing operations includes a deferred income tax benefit of $58 million associated with winding down a subsidiary.
(f) | Includes pre-tax charges of $24 million, primarily associated with workforce reductions and professional fees incurred in connection with further restructuring and integrating the Company ($12 million in cost of services and $12 million in selling, general and administrative expenses); and pre-tax charges in selling, general and administrative expenses of $4 million, principally representing costs incurred related to legal matters.
(g) | Includes pre-tax charges of $27 million, primarily associated with workforce reductions and professional fees incurred in connection with further restructuring and integrating the Company ($11 million in cost of services and $16 million in selling, general and administrative expenses); and pre-tax charges in selling, general and administrative expenses of $7 million, principally representing costs incurred related to legal matters.
(h) | Includes pre-tax charges of $40 million, primarily associated with workforce reductions and professional fees incurred in connection with further restructuring and integrating the Company ($14 million in cost of services, $25 million in selling, general and administrative expenses and $1 million in other operating expense (income), net); and pre-tax charges in selling, general and administrative expenses of $8 million, principally representing costs incurred related to legal matters.
(i) | Includes pre-tax charges of $30 million, primarily associated with workforce reductions and professional fees incurred in connection with further restructuring and integrating the Company ($13 million in cost of services, $16 million in selling, general and administrative expenses and $1 million in other operating expense (income), net); pre-tax charges in selling, general and administrative expenses of $5 million, principally representing costs incurred related to legal matters; and a pre-tax gain included in other operating expense (income), net of $9 million associated with a decrease in the fair value of the contingent consideration accrual associated with the Summit Health acquisition (see Note 5 and Note 7). Income from continuing operations includes a discrete benefit of $44 million associated with the favorable resolution of certain tax contingencies.

X
- References No definition available. + Details
Name: | us-gaap_QuarterlyFinancialDataAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 13 -URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e765-108305 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a)-(j) -URI http://asc.fasb.org/extlink&oid=51825399&loc=d3e1280-108306 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 270 -SubTopic 10 -Section 45 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=51655806&loc=d3e725-108305 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Staff Accounting Bulletin (SAB) -Number Topic 6 -Section G -Subsection 1 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K (SK) -Number 229 -Section 302 -Paragraph a + Details
Name: | us-gaap_QuarterlyFinancialInformationTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration